Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

925
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
925
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

176
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
176
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

209
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
209
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

206
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
206
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

1.8K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
1.8K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Complicated versus uncomplicated amoebic liver abscess in adult: A prospective analysis of clinical presentation, disease course, and outcomes.

Tropical doctor·2026
Same author

High-density lipoprotein cholesterol at admission reflects disease course, severity, and influences management decisions in patients with amoebic liver abscess.

Tropical doctor·2025
Same author

Hypochloremia is an underutilised prognostic marker in patients with advanced liver cirrhosis and liver failure.

World journal of hepatology·2025
Same author

Effect of pantoprazole as an adjunct to standard medical therapy in patients with uncomplicated amoebic liver abscess: A randomised pilot study.

Tropical doctor·2025
Same author

Amebic liver abscess: An update.

World journal of hepatology·2024
Same author

Serum Vitamin D Level as a Risk Factor and Prognostic Marker for Acute Ischemic Stroke: A Case-Control Study at a Tertiary Care Centre in Northern India.

Cureus·2023

相关实验视频

Updated: Jan 12, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

7.3K

乙型肝炎的功能疗法:当前和未来的前景.

Sudheer Marrapu1, Jinit R Soni1, Kislaya Kamal1

  • 1Department of Gastroenterology, All India Institute of Medical Sciences, Patna 801507, India.

World journal of hepatology
|November 3, 2025
PubMed
概括

实现慢性乙型肝炎 (CHB) 的功能治愈需要乙型肝炎表面抗原 (HBsAg) 的损失. 目前的治疗方法表现出有限的成功,需要新的疗法来克服CHB发病障碍.

关键词:
功能疗法是一种功能疗法.乙型肝炎 B 型肝炎乙型肝炎表面抗原的血清清除表面抗原是一种抗原.病毒学疗法可以治愈病毒.

更多相关视频

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.6K
Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix
10:37

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix

Published on: October 20, 2021

3.4K

相关实验视频

Last Updated: Jan 12, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

7.3K
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.6K
Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix
10:37

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix

Published on: October 20, 2021

3.4K

科学领域:

  • 肝病学 肝病学是一种肝病学.
  • 病毒学 病毒学
  • 免疫学 免疫学 免疫学

背景情况:

  • 慢性乙型肝炎 (CHB) 影响全球超过2.5亿人.
  • 功能性治疗,标志着HBsAg损失和无法检测到的HBVDNA,是治疗的主要目标.
  • 包括病毒DNA整合和免疫功能障碍在内的CHB病变,阻碍HBsAg清除.

研究的目的:

  • 审查当前对HBsAg血清清除在CHB中的理解.
  • 讨论CHB的临床意义和实现功能治疗的挑战.
  • 探索CHB不断变化的治疗环境.

主要方法:

  • 关于CHB病原和治疗的当前文献的综述.
  • 对HBsAg血清清除现有治疗结果的分析.
  • 讨论新型治疗策略及其潜力.

主要成果:

  • 目前的治疗方法 (NAs,基化干扰素) 产生较低的HBsAg血清清除率 (3-14%).
  • 对HBsAg清除的重大障碍包括病毒持久性和免疫力受损.
  • 新型抗病毒药物和免疫疗法正在研究中.

结论:

  • 由于复杂的病毒和宿主因素,实现CHB的功能治疗仍然具有挑战性.
  • 针对HBV生命周期和免疫反应的新疗法至关重要.
  • 仔细选择患者进行NA终止可能有助于HBsAg损失,但需要谨慎监测.